Katie King is a British scientist and entrepreneur who co-founded BioOrbit, a London-based company attempting something no one has managed before: manufacturing cancer medicines in orbit and bringing them back to Earth. Most people arrive at her name from one of two very different directions. Some find her through space-industry and biotech coverage, where she is discussed as one of the few founders bridging pharmaceutical manufacturing and low-Earth orbit. Others find her through entertainment media, because she is Carol Vorderman’s daughter, and the Countdown presenter has spoken warmly and often about her daughter’s work in cancer research. Both routes lead to the same person, but they tell very different halves of the story.
Who Is Katie King?
Katie King is the co-founder and chief executive of BioOrbit, a UK space-biotech company founded in 2023 alongside oncology researcher Dr Leonor Teles. She holds a doctorate from the University of Cambridge and is usually credited as Dr Katie King in professional settings, which is a useful distinction because the name itself is common and search results frequently blend several unrelated people. Her specific field is protein crystallisation in microgravity, a narrow and technical corner of pharmaceutical science that has only recently become commercially plausible. Public interest in her spiked sharply in April 2026 when BioOrbit announced a seed funding round widely reported as the largest ever raised for in-space manufacturing, but she had already built a visible profile before that through speaking appearances at Slush, SXSW London and London Tech Week. She is also known within the UK technology sector as an advocate for women in STEM and serves as an ambassador for Tech She Can, a role she has described as connected to her own experience of being encouraged into science by a teacher who took her ambitions seriously.
Background in Nanomedicine and Space Science
Katie King’s scientific training sits at the intersection of chemistry, medicine and materials, which explains why her current company looks so unusual on paper. She completed a PhD in nanomedicine at the University of Cambridge in 2022, working on targeted drug delivery using nanoparticles, and her published research includes work on the self-assembly of nanoparticles using cucurbituril-based binding motifs. Before and during that period she built an unusually broad set of placements: an internship with NASA working on sample analysis for the Mars team, studying signs of past life on Mars, and research experience with the pharmaceutical company AstraZeneca. Alongside her academic career she served for several years as a Royal Air Force volunteer reservist, and earlier reporting from 2014 described her as studying physics at Cambridge while training as an RAF pilot, an ambition tied to her hope at the time of becoming an astronaut. The pivotal moment came in 2022 at the International Space University’s summer programme, where the idea that would become BioOrbit took shape. That combination of nanomedicine, oncology-adjacent drug delivery, aerospace exposure and military discipline is rare, and it is the honest explanation for why a Cambridge chemist ended up building hardware for orbit.
Marriage or Relationship Status: Not Publicly Disclosed
Katie King’s marital status and relationship history have not been publicly disclosed, and no verified interview, official company biography or reputable news report identifies a spouse or partner. This is worth stating plainly rather than filling with speculation, because the gap in the record is genuine and not an oversight. Unlike her mother, whose personal life has been reported on for decades, Katie King has kept her public presence almost entirely professional: her interviews, podcasts and conference appearances deal with crystallisation science, regulatory pathways for space-manufactured medicines, and the challenge of raising venture capital for hardware that has to survive re-entry. Many of the pages that appear to answer questions about her private life are automated aggregator sites that reproduce guesses rather than confirmed facts, and readers should treat those with caution. If reliable information about her relationship status enters the public domain through her own statements or credible reporting, it would be reasonable to reflect it; until then, the accurate answer is that it has not been shared.
Parenthood and Family Life
Katie King’s family of origin is well documented, while her own family situation is not. She is the daughter of Carol Vorderman, the broadcaster and mathematician best known for three decades on Countdown, and Patrick King, a management consultant; the couple married in 1990 and separated in 2000. She has a younger brother, Cameron King, and the family has occasionally appeared together in public and on social media. Carol Vorderman has spoken publicly about her daughter’s work on several occasions, including describing her as a research scientist working on cancer drug delivery using nanotechnology in Cambridge, and connecting that work to the family’s own experience of cancer after Vorderman’s mother Jean died of the disease. In 2020 the two collaborated professionally when Katie taught alongside her mother on The Maths Factor, Vorderman’s online maths school, for the Year 7 material. Whether Katie King has children of her own has not been publicly disclosed, and no credible source addresses the question.
Supporting Cancer Patients Through At-Home Treatment
The problem BioOrbit is trying to solve is a practical one that patients feel directly. Roughly seventy per cent of the world’s highest-grossing drugs are administered intravenously in a clinical setting, meaning patients on antibody-based cancer therapies must travel to hospital, sit through infusions and depend on clinical staff for every dose. High-concentration antibody formulations are usually too viscous to inject under the skin, which is why the subcutaneous alternative has been so difficult to achieve. Katie King’s thesis is that crystallising those antibodies removes the viscosity barrier, in much the same way that diabetics self-inject suspensions of crystalline insulin rather than a thick solution, and that microgravity produces more uniform, more highly ordered crystals than gravity-bound labs can. BioOrbit’s hardware for this is called BOX, a modular, autonomous unit roughly the size of a microwave that runs crystallisation in orbit without a crew, designed to move the process from a one-off experiment towards industrial scale. If it works at volume, the practical result is cancer treatment moving from the hospital ward into the home, with the company projecting substantial cost reductions for health systems, though it is important to be clear that this remains an in-development technology rather than an approved clinical product.
Life After BioOrbit’s Record-Breaking Seed Round
April 2026 marked the clearest step change in Katie King’s career so far. BioOrbit announced £9.8 million (approximately $13.2 million) in seed funding, co-led by LocalGlobe and Breega with participation from Auxxo, Seedcamp, Type One Ventures, 7percent Ventures and undisclosed angel investors, in what was reported as the largest seed round ever raised for in-space manufacturing. The money is earmarked for the shift from demonstration to industrial deployment, including an office on the US East Coast, and the company simultaneously brought in two senior figures from Redwire: Dr Molly Mulligan as president of BioOrbit Inc., credited with signing the first in-orbit pharmaceutical royalty agreement, and Dr Ken Savin as chief science officer, who spent two decades at Eli Lilly before leading ISS research and development commercialisation. Around the same period the company signed a memorandum of understanding with Vast to explore flying its crystallisation platform on Haven commercial space stations, giving it the repeat orbital access that scaled production requires. BioOrbit had earlier flown its first payload in 2025 with The Exploration Company to test how protein crystals survive re-entry, and it has been named among Tech Nation’s Future Fifty companies. The regulatory side has moved too: in March 2026 the UK government and the Medicines and Healthcare products Regulatory Agency established a framework for approving and safety-testing space-manufactured drugs, a world first that BioOrbit helped shape through work with the UK Space Agency, the Regulatory Innovation Office and the Civil Aviation Authority.
Career Highlights and Public Recognition
Recognition for Katie King has come from the technology, space and healthcare sectors rather than from media coverage of her family. She won the Innovator Award at the 2024 Everywoman in Technology Awards, cited for innovation at BioOrbit and for championing women in STEM, and was named a Top Female Innovator in Codex World’s list of leading innovators the same year. BioOrbit passed through Seraphim’s space accelerator and was later selected as a Rising Star by Founders Forum Group, a cohort that has previously included Bumble, DeepMind and Wayve. She has spoken at Slush 2025, SXSW London, London Tech Week and Space-Comm, appeared on healthcare and business podcasts to explain the science behind crystallisation, and attended a Downing Street reception for UK technology companies. British astronaut Tim Peake has publicly praised the company’s approach, describing it as turning imagination into real progress for patients on Earth. Perhaps the most substantive marker of credibility, though, is less glamorous than any award: BioOrbit has attracted interest from the NHS and the UK Space Agency and has been directly involved in writing the regulatory rulebook for medicines made off-planet.
Why People Search for Katie King
Search interest in Katie King splits into distinct groups with genuinely different questions, which is why so much of the content about her feels mismatched to what readers actually want. Investors, journalists and people working in space and biotech are looking for the founder story, the funding history, the technical claims behind microgravity crystallisation and the credibility of the team around her. A second group arrives after seeing her mother mentioned in the press and wants the family connection explained, often searching directly for Carol Vorderman’s daughter to confirm whether the scientist and the celebrity relative are the same person. A third group comprises students, particularly young women considering physics, chemistry or engineering, who encounter her through Tech She Can, school outreach or a conference keynote and want to know how someone builds a career that runs from an RAF cadet unit to a Cambridge doctorate to a space company. There is also a persistent stream of searches driven by name confusion, since several unrelated public figures share the name. Understanding which of these you are is the fastest way to find useful information rather than recycled celebrity filler.
Privacy, Accuracy and Public Information
Writing responsibly about Katie King means separating three tiers of information. The first tier is corporate and professional and is well sourced: her role at BioOrbit, her Cambridge doctorate, the company’s funding, partnerships, hardware and regulatory work are all documented in trade publications, company announcements, conference listings and her own interviews. The second tier is family information she and her mother have chosen to share publicly, including the parental relationship, her brother, and the collaboration on The Maths Factor. The third tier covers her private life, and here the honest position is that very little has been disclosed and none of it should be inferred. A great deal of what circulates online about her personal circumstances, including age-adjacent details, relationship claims and financial estimates, originates from automated profile sites that copy from one another without verification, and net worth figures in particular have no reliable public basis and are not repeated here. Being someone’s daughter does not transfer that person’s level of public exposure, and a founder who discusses her work openly has not thereby invited scrutiny of everything else.
FAQs
What does Katie King do?
Katie King is co-founder and CEO of BioOrbit, a UK company developing hardware that crystallises protein-based drugs in microgravity so cancer treatments can eventually be self-injected at home.
Is Katie King really Carol Vorderman’s daughter?
Yes. Katie King is the daughter of broadcaster Carol Vorderman and management consultant Patrick King, who married in 1990 and separated in 2000. She has a younger brother, Cameron.
Where did Katie King study?
She studied at the University of Cambridge, completing a PhD in nanomedicine in 2022. Earlier reporting says she read physics there while training with the Royal Air Force.
Is Katie King married?
Her relationship status has not been publicly disclosed. Neither Katie King nor her family has shared details about a spouse or partner in verified interviews or official company profiles.
How much funding has BioOrbit raised?
BioOrbit announced a £9.8 million seed round in April 2026, co-led by LocalGlobe and Breega. Reports described it as the largest seed round for in-space manufacturing.
Has Katie King been to space?
No. She has not flown to space. Her teenage ambition was to become an astronaut, but her current work involves sending manufacturing hardware into orbit rather than herself.
Conclusion
Katie King occupies an unusual position in British public life: a scientist whose work is technically demanding and commercially unproven, attached to a surname that guarantees attention regardless of what she does. The fair reading of the record is that the attention arrived first through her mother and has since been earned independently, through a Cambridge doctorate, a company that has raised the largest seed round in its category, partnerships with commercial space station operators, and a genuine hand in shaping how regulators will approve medicines manufactured beyond Earth. None of that guarantees BioOrbit will succeed; manufacturing pharmaceuticals in orbit at industrial scale remains an open engineering and regulatory question, and the pre-clinical and compliance stages ahead are long. What can be said accurately today is that Katie King is a nanomedicine specialist running a serious attempt at a hard problem, that the connection to Carol Vorderman is real but explains almost nothing about her career, and that anything beyond her professional life remains, by her own choice, undisclosed.
